MeCure Industries Plc’s latest audited results tell a two-year story of strain and payoff.
In 2024, the pharmaceutical company grew revenue by 45 percent to N46.03 billion, yet profit after tax fell 20 percent to N2.3 billion. Twelve months later, profit surged 183 percent to N6.5 billion as revenue accelerated to N77.69 billion.
The swing from earnings squeeze to breakout reflects a deliberate, debt-funded expansion that collided with Nigeria’s high-interest-rate cycle before beginning to yield returns.
